These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24695735)

  • 1. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
    Ray S; Bender S; Kang S; Lin R; Glicksman MA; Liu M
    J Biol Chem; 2014 May; 289(19):13042-53. PubMed ID: 24695735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.
    Ohta E; Kawakami F; Kubo M; Obata F
    Biochem Biophys Res Commun; 2013 Jan; 430(2):560-6. PubMed ID: 23220480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.
    Liu M; Kang S; Ray S; Jackson J; Zaitsev AD; Gerber SA; Cuny GD; Glicksman MA
    Biochemistry; 2011 Nov; 50(43):9399-408. PubMed ID: 21961647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
    Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR
    Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
    J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.
    Gilsbach BK; Ho FY; Vetter IR; van Haastert PJ; Wittinghofer A; Kortholt A
    Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10322-7. PubMed ID: 22689969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis.
    Ohta E; Kubo M; Obata F
    Biochem Biophys Res Commun; 2010 Jan; 391(1):242-7. PubMed ID: 19912990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
    Kamikawaji S; Ito G; Sano T; Iwatsubo T
    Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
    Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
    J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.
    Ohta E; Nihira T; Uchino A; Imaizumi Y; Okada Y; Akamatsu W; Takahashi K; Hayakawa H; Nagai M; Ohyama M; Ryo M; Ogino M; Murayama S; Takashima A; Nishiyama K; Mizuno Y; Mochizuki H; Obata F; Okano H
    Hum Mol Genet; 2015 Sep; 24(17):4879-900. PubMed ID: 26056228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2).
    Lovitt B; Vanderporten EC; Sheng Z; Zhu H; Drummond J; Liu Y
    Biochemistry; 2010 Apr; 49(14):3092-100. PubMed ID: 20205471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
    Covy JP; Giasson BI
    J Neurochem; 2010 Oct; 115(1):36-46. PubMed ID: 20626563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.